Trial Profile
A Phase 1, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of oral ETX0282 Administered in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Cefpodoxime/ETX 0282 (Primary) ; Cefpodoxime proxetil
- Indications Enterobacteriaceae infections; Gram-negative infections; Urinary tract infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Entasis Therapeutics
- 13 Jan 2020 Status changed from active, no longer recruiting to completed.
- 05 Sep 2019 Planned number of patients changed from 144 to 112.
- 05 Sep 2019 Planned End Date changed from 1 Jul 2019 to 1 Sep 2019.